Fig 1: I/R increases the expression and secretion of MANF in the heart. A Western blot analysis was used to determine MANF levels in HL-1 treated with H/R, with quantitative bands normalized to β-Tubulin. B-C Representative immunofluorescence staining and statistical quantification of MANF (red), Calnexin (green) and DAPI (blue) in HL-1 subjected to H/R treatment, with Calnexin labeling the ER. Scale bar, 25 μm. D Serum levels of MANF in MI patient (n = 20) and healthy control (n = 20). E Serum levels of MANF in I/R mice (n = 6) and normal mice (n = 6). F-G Representative immunohistochemical images and statistical quantification of MANF expression in I/R mice and normal mice using anti-MANF antibody. Scale bar, 25 μm. H Western blot analysis and quantification of MANF levels in I/R mice. I-J Representative immunofluorescence staining and statistical quantification of MANF (red), α-actin (green) and DAPI (blue) in I/R mice, with α-actin marking actin fibers. Scale bar, 25 μm. Data are presented as mean ± SD and represent at least 3 independent experiments. **P<0.01, ***P<0.001, ****P<0.0001
Fig 2: Myeloid MANF knockout promotes Ly6Chigh macrophages recruitment in liver. (A) Myeloid MANF deficiency increased the proportion of hepatic CD11bhighF4/80lowLy6Chigh mono-macrophages detected by flow cytometry. (B, C) The quantitative data in vehicle-treated (B) and CCl4-treated (C) mice were calculated. (D, E) The expressions of CCL2 and CX3CL1 were detected by immunohistochemistry (D) and qPCR (E). The integral optical density was calculated. (F–H) Myeloid MANF deficiency increased serum TNF-α (F), IL-1β (G), and CCL2 (H) levels detected by ELISA. Data are expressed as mean ± SEM, n = 10; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. WT, wild type; HKO, MANF knockout in hepatocytes; MKO, MANF knockout in myeloid cells; CCl4, carbon tetrachloride.
Fig 3: VB protected APP/PS1 mice against ER stress. VB reduced the concentrations of the following proteins related to ER stress in mice brains by ELISA: a MANF, b BiP, c ATF6, d p-IRE1/IRE1, e XBP1, f p-PERK/PERK, g p-eIF2α/eIF2α, h ATF4, i CHOP, and j caspase 12. The data are presented as mean ± SEM (n = 8/group). #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. WT mice, *p < 0.05 and ***p < 0.001 vs. APP/PS1 mice
Fig 4: Sulfatide binding is critical for cytoprotection by MANF in culture. a Lipid overlay assay showing secreted V5-tagged Hs-MANF and recombinant His-tagged Hs-MANF bound to sulfatide (left), with secreted Hs-MANF::V5 confirmed by western blot of cell lysate and medium (right). HSP90 was used as a loading control. b Size exclusion chromatography of wild-type Hs-MANF and K112L mutants reconstituted in 0.05% Tween-20 and sulfatide. Only 20% of the K112L mutant Hs-MANF was bound onto the micelle fraction compared with 50% of the wild-type Hs-MANF. c Lipid overlay assay (above) showing that secreted MANF (K112L) from HEK293T cell lines exhibited markedly reduced binding to sulfatide with western blot (bottom) showing normal protein levels in the HEK293T stable line. d Death rates of HEK293T cells after 48 h of 0.1% hypoxia with pretreatment of Hs-MANF or MANF (K112L) mutant-conditioned media or with additional anti-sulfatide O4 antibodies. e Death rates of HEK293T cells after 24 h of indicated treatment followed by 40 h exposure to 0.5 µM thapsigargin (Tg). Error bars: S.E. with ***P < 0.001 (N ≥ 3 independent biological replicates)
Fig 5: Reducing PIP4k2b ameliorates MANF mediated insulin resistance. a Representative western blotting images (from three independent experiments) of pAKT levels in PC12 cells treated with insulin (Ins) for different lengths of time: untreated (−), 10 min or 30 min. b Quantification of western blotting results in Fig. 8a (*P < 0.05, ***P < 0.001, n = 4, one-way ANOVA with Tukey post-tests, F = 39.17, P < 0.0001). c GFP fluorescence was used to indicate the areas with shRNA expression in mice injected with either AAV-scramble-shRNA or AAV-PIP4k2b-shRNA (Scale bar: 100 μm). d Food intake of MANF TG mice injected with either AAV-scramble-shRNA or AAV-PIP4k2b-shRNA was measured weekly after viral injection (*P < 0.05, n = 6, two-way ANOVA with Bonferroni post-tests, F = 23.17, P < 0.0001). e Body weights of MANF TG mice injected with either AAV-scramble-shRNA or AAV-PIP4k2b-shRNA were measured weekly after viral injection (*P < 0.05, n = 6, two-way ANOVA with Bonferroni post-tests, F = 23.63, P < 0.0001). f Representative western blotting images (from three independent experiments) of pAKT levels in MANF TG mice injected with either AAV-scramble-shRNA (Scramble) or AAV-PIP4k2b-shRNA (PIP) in the hypothalamus, and then treated with insulin. g Quantification of western blotting results in Fig. 8f (*P < 0.05, ***P < 0.001, n = 3; 2-tailed student t test, pAKT, t = 3.323, P = 0.0399; PIP4k2b, t = 33.09, P = 0.0009). Data are represented as mean ± SEM. h The proposed model of the function of MANF in mediating insulin signaling and food intake
Supplier Page from Abcam for Anti-ARMET/ARP antibody